Avalo Therapeutics (AVTX) Accumulated Expenses (2014 - 2026)

Avalo Therapeutics (AVTX) has 13 years of Accumulated Expenses data on file, last reported at $327000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 92.85% year-over-year to $327000.0; the trailing twelve-month figure through Mar 2026 stood at $327000.0 (down 92.85% YoY), and the FY2025 full-year result was $2.0 million, up 511.62% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $327000.0, down from $2.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $14.1 million in Q1 2022 and bottomed at $214000.0 in Q3 2023.
• The 5-year median for Accumulated Expenses is $2.0 million (2022), against an average of $3.6 million.
• The widest annual swing landed in 2023, when Accumulated Expenses sank 95.41%; it then soared 3186.45% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then slumped by 83.65% to $327000.0 in 2024, then surged by 511.62% to $2.0 million in 2025, then slumped by 83.65% to $327000.0 in 2026.
• The last three Accumulated Expenses figures came in at $327000.0 (Q1 2026), $2.0 million (Q4 2025), and $327000.0 (Q3 2025), per Business Quant data.

Peer Comparison